Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
Status:
Completed
Trial end date:
2018-05-22
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety of the investigational drug called
cirmtuzumab when given for a duration of 6 to 12 months. Cirmtuzumab is a type of drug called
a monoclonal antibody. This drug is designed to attach to a protein called ROR1 that is on
the surface of chronic lymphocytic leukemia (CLL) cells. This blocks growth and survival of
the CLL cells. ROR1 is rarely expressed on healthy cells so this drug should target the
cancer cells. Cirmtuzumab is considered experimental because its use is not approved by
United States (US) Food and Drug Administration (FDA).
Although there is evidence from tests on laboratory animals that cirmtuzumab can decrease the
number of CLL cells, the investigators do not know if this will work in humans. Therefore,
the goal of this study is to see if cirmtuzumab is safe and tolerable in study participants
when given for a duration of 6 to 12 months.